Search

Your search keyword '"R. Gaur"' showing total 12 results
Start Over Author "R. Gaur" Topic medicine.medical_specialty
12 results on '"R. Gaur"'

1. MA13.01 A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study

Author

Elizabeth Gore, Feng Ming Kong, J. Rothman, Samir Narayan, Jeffrey A. Bogart, Weili Wang, J. Welsh, Julie A. Bradley, V.S. Kavadi, Robert MacRae, R. Gaur, G.M. Cannon, C.D. Koprowski, I.Y. Garces, B. Lu, Cliff G. Robinson, JianYue Jin, Chen Hu, and Mitchell Machtay

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Validation study, business.industry, DNA repair, Internal medicine, Secondary analysis, medicine, business, Lung cancer, medicine.disease
Published
2021

2. Radiomic Biomarkers Evaluation of the High Dose Arm of RTOG 0617

Author

M. Rosen, Samir Narayan, Walter J. Curran, Yolanda I. Garces, Puneeth Iyengar, Gregory M.M. Videtic, J. Cao, Robert MacRae, R. Gaur, H. Geng, Anthony T. Pu, Jeffrey D. Bradley, V.S. Kavadi, N. Sasankan, James W. Welsh, Y. Fan, C.D. Koprowski, Cliff G. Robinson, Y. Xiao, and Haoyu Zhong

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2019

3. Hematologic Toxicity in RTOG 0418: A Phase 2 Study of Postoperative IMRT for Gynecologic Cancer

Author

Mohammad Salehpour, Brigitte Miller, Jennifer Moughan, Luis Souhami, Lorraine Portelance, Anuja Jhingran, David D'Souza, Ann H. Klopp, R. Gaur, Jenny Nuanjing, Evangeline Hildebrandt, and William Small

Subjects
Organs at Risk, Oncology, Radiation-Sensitizing Agents, Cancer Research, medicine.medical_treatment, Uterine Cervical Neoplasms, Phases of clinical research, Bone Marrow, Intestine, Small, Prospective Studies, Prospective cohort study, Cervical cancer, Radiation, Common Terminology Criteria for Adverse Events, Middle Aged, Combined Modality Therapy, medicine.anatomical_structure, Vagina, Regression Analysis, Female, medicine.drug, Adult, medicine.medical_specialty, Urinary Bladder, Urology, Radiation Dosage, Article, Pelvis, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Pelvic Bones, Radiation Injuries, Aged, Postoperative Care, Cisplatin, Lymphatic Irradiation, business.industry, Endometrial cancer, medicine.disease, Endometrial Neoplasms, Radiation therapy, Feasibility Studies, Radiotherapy, Intensity-Modulated, Bone marrow, business, Organ Sparing Treatments
Abstract

Purpose Intensity modulated radiation therapy (IMRT), compared with conventional 4-field treatment, can reduce the volume of bone marrow irradiated. Pelvic bone marrow sparing has produced a clinically significant reduction in hematologic toxicity (HT). This analysis investigated HT in Radiation Therapy Oncology Group (RTOG) 0418, a prospective study to test the feasibility of delivering postoperative IMRT for cervical and endometrial cancer in a multiinstitutional setting. Methods and Materials Patients in the RTOG 0418 study were treated with postoperative IMRT to 50.4 Gy to the pelvic lymphatics and vagina. Endometrial cancer patients received IMRT alone, whereas patients with cervical cancer received IMRT and weekly cisplatin (40 mg/m 2 ). Pelvic bone marrow was defined within the treatment field by using a computed tomography density-based autocontouring algorithm. The volume of bone marrow receiving 10, 20, 30, and 40 Gy and the median dose to bone marrow were correlated with HT, graded by Common Terminology Criteria for Adverse Events, version 3.0, criteria. Results Eighty-three patients were eligible for analysis (43 with endometrial cancer and 40 with cervical cancer). Patients with cervical cancer treated with weekly cisplatin and pelvic IMRT had grades 1-5 HT (23%, 33%, 25%, 0%, and 0% of patients, respectively). Among patients with cervical cancer, 83% received 5 or more cycles of cisplatin, and 90% received at least 4 cycles of cisplatin. The median percentage volume of bone marrow receiving 10, 20, 30, and 40 Gy in all 83 patients, respectively, was 96%, 84%, 61%, and 37%. Among cervical cancer patients with a V40 >37%, 75% had grade 2 or higher HT compared with 40% of patients with a V40 less than or equal to 37% ( P =.025). Cervical cancer patients with a median bone marrow dose of >34.2 Gy also had higher rates of grade ≥2 HT than did those with a dose of ≤34.2 Gy (74% vs 43%, P =.049). Conclusions Pelvic IMRT with weekly cisplatin is associated with low rates of HT and high rates of weekly cisplatin use. The volume of bone marrow receiving 40 Gy and the median dose to bone marrow correlated with higher rates of grade ≥2 toxicity among patients receiving weekly cisplatin (cervical cancer patients). Evaluation and limitation of the volume of bone marrow treated with pelvic IMRT is warranted in patients receiving concurrent chemotherapy.

Published
2013

4. MEDICAL AND NEURO-ONCOLOGY

Author

G. K. Prithviraj, S. R. Sommers, R. L. Jump, B. Halmos, L. B. Chambless, S. L. Parker, L. Hassam-Malani, M. J. McGirt, R. C. Thompson, K. Hunter, M. C. Chamberlain, E. M. Le, E. L. T. Lee, Z. S. Sadighi, M. L. Pearlman, J. M. Slopis, T. S. Vats, S. Khatua, N. C. DeVito, M. Yu, R. Chen, E. Pan, T. Cloughesy, J. Raizer, J. Drappatz, M. Gerena-Lewis, J. Rogerio, S. Yacoub, A. Desjardin, M. D. Groves, J. DeGroot, M. Loghin, C. A. Conrad, K. Hess, J. Ni, S. Ictech, W. A. Yung, A. B. Porter, A. C. Dueck, N. J. Karlin, J. Olson, J. Silber, A. S. Reiner, K. S. Panageas, F. M. Iwamoto, T. F. Cloughesy, K. D. Aldape, A. L. Rivera, A. F. Eichler, D. N. Louis, N. A. Paleologos, B. J. Fisher, L. S. Ashby, J. G. Cairncross, G. B. Roldan, P. Y. Wen, K. L. Ligon, D. Shiff, H. I. Robins, B. G. Rocque, W. P. Mason, S. A. Weaver, R. M. Green, F. G. Kamar, L. E. Abrey, L. M. DeAngelis, S. C. Jhanwar, M. K. Rosenblum, A. B. Lassman, D. Cachia, L. Alderson, R. Moser, T. Smith, S. Yunus, K. Saito, A. Mukasa, Y. Narita, Y. Tabei, N. Shinoura, S. Shibui, N. Saito, B. Flechl, M. Ackerl, C. Sax, K. Dieckmann, R. Crevenna, G. Widhalm, M. Preusser, C. Marosi, C. Ay, D. Dunkler, I. Pabinger, C. Zielinski, M. Belongia, S. Jogal, K.-H. Schlingensiepen, U. Bogdahn, G. Stockhammer, A. K. Mahapatra, N. K. Venkataramana, V. Oliushine, V. Parfenov, I. Poverennova, P. Hau, P. Jachimczak, H. Heinrichs, A. G. Mammoser, N. A. Shonka, J. F. de Groot, I. Shibahara, Y. Sonoda, T. Kumabe, R. Saito, M. Kanamori, Y. Yamashita, M. Watanabe, C. Ishioka, T. Tominaga, A. Silvani, P. Gaviani, E. Lamperti, A. Botturi, F. DiMeco, G. Broggi, L. Fariselli, C. L. Solero, A. Salmaggi, E. A. Woyshner, F. Shu, Y. S. Oh, S. Iganej, G. Singh, S. L. Vemuri, B. J. Theeler, B. Ellezam, M. R. Gilbert, T. Aoki, H. Kobayashi, S. Takano, R. Nishikawa, M. Nagane, Y. Muragaki, K. Sugiyama, J. Kuratsu, M. Matsutani, L. A. Langford, V. K. Puduvalli, D. Shen, Z.-p. Chen, J.-p. Zhang, D. Bedekar, S. Rand, J. Connelly, M. Malkin, E. Paulson, W. Mueller, K. Schmainda, O. Gallego, M. Benavides, P. P. Segura, C. Balana, M. Gil, A. Berrocal, G. Reynes, J. L. Garcia, P. Murata, S. Bague, M. J. Quintana, V. G. Vasishta, K. Kobayashi, M. Tanaka, K. Tsuchiya, Y. Shiokawa, A. A. Bavle, K. Ayyanar, M. P. Prado, K. R. Hess, V. Liu, J. de Groot, M. E. Loghin, H. Colman, V. A. Levin, W. K. Alfred Yung, J. R. Hackney, C. A. Palmer, J. M. Markert, J. Cure, K. O. Riley, H. Fathallah-Shaykh, L. B. Nabors, M. G. Saria, C. Corle, J. Hu, J. Rudnick, S. Phuphanich, M. M. Mrugala, L. K. Lee, B. D. Fu, D. A. Bota, R. Y. Kim, T. Brown, H. Feely, A. Hu, J. W. Lee, B. Carter, S. Kesari, X.-T. Kong, S. Sparagana, E. Belousova, S. Jozwiak, B. Korf, M. Frost, R. Kuperman, M. Kohrman, O. Witt, J. Wu, R. Flamini, A. Jansen, P. Curtalolo, E. Thiele, V. Whittemore, P. De Vries, J. Ford, G. Shah, H. Cauwel, P. Edrich, T. Sahmoud, D. Franz, M. Khasraw, C. Brown, D. M. Ashley, M. A. Rosenthal, X. Jiang, Y. g. Mou, Z. p. Chen, M. Oh, E. kim, J. Chang, T. A. Juratli, M. Kirsch, G. Schackert, D. Krex, M. Wang, R. Stupp, M. Hegi, K. A. Jaeckle, T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran, M. P. Mehta, K. F. Hofland, S. Hansen, M. Sorensen, H. Schultz, A. Muhic, S. Engelholm, A. Ask, C. Kristiansen, C. Thomsen, H. S. Poulsen, U. N. Lassen, O. Zalatimo, C. Weston, C. Zoccoli, M. Glantz, S. Rahmanuddin, M. S. Shiroishi, S. Y. Cen, J. Jones, T. Chen, P. Pagnini, J. Go, A. Lerner, J. Gomez, M. Law, Z. Ram, E. T. Wong, P. H. Gutin, M. S. Bobola, M. Alnoor, D. L. Silbergeld, R. C. Rostomily, J. R. Silber, N. Martha, S. Jacqueline, G. Thaddaus, P. Daniel, M. Hans, M. Armin, T. Eugen, S. Gunther, M. Hutterer, H.-M. Tseng, C. M. Zoccoli, A. Patel, K. Rizzo, J. M. Sheehan, A. L. Sumrall, J. J. Vredenburgh, A. Desjardins, D. A. Reardon, H. S. Friiedman, K. B. Peters, L. P. Taylor, M. Stewart, N. A. Blondin, J. M. Baehring, T. Foote, N. Laack, J. Call, M. G. Hamilton, S. Walling, M. Eliasziw, J. Easaw, N. V. Shirsat, R. Kundar, A. Gokhale, A. Goel, A. A. Moiyadi, J. Wang, E. Mutlu, A. Oyan, T. Yan, O. Tsinkalovsky, H. K. Jacobsen, K. M. Talasila, L. Sleire, K. Pettersen, H. Miletic, S. Andersen, S. Mitra, I. Weissman, X. Li, K.-H. Kalland, P. O. Enger, J. Sepulveda, C. Belda, R. Sitt, L. Phishniak, F. Bokstein, M. Philippe, C. Carole, M. d. P. Andre, B. Marylin, C. Olivier, O. L'Houcine, F.-B. Dominique, N.-M. Isabelle, F. Frederic, F. Stephane, D. Henry, M. A. Errico, L. J. Kunschner, R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. G. Fabrini, I. Lolli, R. Jalali, P. K. Julka, A. K. Anand, D. Bhavsar, N. Singhal, R. Naik, S. John, B. S. Mathew, I. Thaipisuttikul, J. Graber, M. Shirinian, A. M. Fontebasso, K. Jacob, N. Gerges, A. Montpetit, A. Nantel, S. Albrecht, N. Jabado, K. Shah, K. Di, M. Linskey, N. Thon, S. Eigenbrod, S. Kreth, J. Lutz, J.-C. Tonn, H. Kretzschmar, A. Peraud, F.-W. Kreth, A. D. Muggeri, J. P. Alderuccio, B. D. Diez, P. Jiang, Y. Chao, M. Gallagher, R. Kim, S. Pastorino, V. Fogal, J. D. Rudnick, C. Bresee, A. Rogatko, S. Sakowsky, M. Franco, S. Lim, A. Lopez, L. Yu, K. Ryback, V. Tsang, M. Lill, A. Steinberg, R. Sheth, S. Grimm, I. Helenowski, A. Rademaker, F. P. Nunes, V. Merker, D. Jennings, P. Caruso, A. Muzikansky, A. Stemmer-Rachamimov, S. Plotkin, A. C. Spalding, T. W. Vitaz, D. A. Sun, S. Parsons, M. R. Welch, A. Omuro, K. Beal, D. Correa, T. Chan, L. DeAngelis, I. Gavrilovic, C. Nolan, A. Hormigo, T. Kaley, I. Mellinghoff, C. Grommes, K. Panageas, A. Reiner, R. Barradas, L. Abrey, P. Gutin, S. Y. Lee, B. Slagle-Webb, M. J. Glantz, J. R. Connor, C. A. Schlimper, H. Schlag, G. Stoffels, F. Weber, D. A. Krueger, M. M. Care, K. Holland, K. Agricola, C. Tudor, A. Byars, D. N. Franz, L. Rice, J. Chandler, R. Levy, K. Muro, L. Nayak, A. D. Norden, T. J. Kaley, A. A. Thomas, C. E. Fadul, L. P. Meyer, E. C. Lallana, M. Gilbert, K. Aldape, J. De Groot, C. Conrad, V. Levin, M. Groves, P. Chris, V. Puduvalli, S. Nagpal, A. Feroze, L. Recht, H. G. Rangarajan, M. W. Kieran, R. M. Scott, S. M. Lew, S. Y. Firat, A. D. Segura, S. A. Jogal, P. U. Kumthekar, S. A. Grimm, M. Avram, J. Patel, V. Kaklamani, K. McCarthy, M. Cianfrocca, W. Gradishar, M. Mulcahy, J. Von Roenn, E. Galanis, S. K. Anderson, J. M. Lafky, T. J. Kaufmann, J. H. Uhm, C. Giannini, S. K. Kumar, D. W. Northfelt, P. J. Flynn, J. C. Buckner, A. I. Omar, D. Schiff, A. Delios, A. Jakubowski, I. Melguizo-Gavilanes, W. Qiao, X. Wang, N. Hashemi-Sadraei, H. Bawa, G. Rahmathulla, M. Patel, P. Elson, G. Stevens, D. Peereboom, M. Vogelbaum, R. Weil, G. Barnett, M. S. Ahluwalia, E. C. Alvord, R. C. Rockne, J. K. Rockhill, R. Rostomily, A. Lai, J. Wardlaw, A. M. Spence, K. R. Swanson, G. Zadeh, H. Alahmadi, J. Wilson, F. Gentili, J. J. Beumer, J. Wright, N. Takebe, R. Gaur, M. Werner-Wasik, A. J. Gupta, A. Campos-Gines, K. Le, C. Arango, M. Richards, M. Landeros, H. Juan, J. H. Chang, J. S. Kim, J. H. Cho, C. O. Seo, A. L. Baldock, R. Rockne, P. Canoll, D. Born, K. Yagle, D. Alexandru, D. Bota, M. E. Linskey, S. Nabeel, S. N. Raval, J. Rosenow, M. Bredel, P. Z. New, S. R. Plotkin, J. G. Supko, W. T. Curry, A. S. Chi, E. R. Gerstner, T. T. Batchelor, N. Hashemi, S. T. Chao, R. J. Weil, J. H. Suh, M. A. Vogelbaum, G. H. Stevens, G. H. Barnett, D. Corwin, C. Holdsworth, R. Stewart, K. Swanson, J. J. Graber, A. R. Anderson, S. Jeyapalan, M. Goldman, J. Boxerman, J. Donahue, H. Elinzano, D. Evans, B. O'Connor, M. Y. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush, A. Santaniello, M. Constantinou, T. DiPetrillo, H. Safran, C. Halpin, F. G. Barker, E. A. Maher, S. Ganji, R. DeBerardinis, K. Hatanpaa, D. Rakheja, X.-L. Yang, T. Mashimo, J. Raisanen, C. Madden, B. Mickey, C. Malloy, R. Bachoo, C. Choi, T. Ranjan, N. Yono, S. J. Han, M. Sun, M. S. Berger, M. Aghi, N. Gupta, and A. T. Parsa

Subjects
Cancer Research, medicine.medical_specialty, Abstracts, Oncology, business.industry, Neuro oncology, medicine, Medical physics, Neurology (clinical), business
Published
2011

5. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418

Author

R. Gaur, Anuja Jhingran, Mohammad Salehpour, William Small, Lorraine Portelance, Kathryn Winter, Brigitte Miller, Luis Souhami, David K. Gaffney, and Lawrence Berk

Subjects
Oncology, Adult, Organs at Risk, Cancer Research, medicine.medical_specialty, Radiography, medicine.medical_treatment, Urinary Bladder, Rectum, Phases of clinical research, Internal medicine, medicine, Carcinoma, Humans, Radiology, Nuclear Medicine and imaging, Adverse effect, Pelvis, Aged, Postoperative Care, Radiation, business.industry, Endometrial cancer, Radiotherapy Planning, Computer-Assisted, Femur Head, Middle Aged, medicine.disease, Surgery, Endometrial Neoplasms, Radiation therapy, Intestines, medicine.anatomical_structure, Vagina, Feasibility Studies, Female, Radiotherapy, Intensity-Modulated, business
Abstract

Purpose To determine the feasibility of pelvic intensity modulated radiation therapy (IMRT) for patients with endometrial cancer in a multi-institutional setting and to determine whether this treatment is associated with fewer short-term bowel adverse events than standard radiation therapy. Methods Patients with adenocarcinoma of the endometrium treated with pelvic radiation therapy alone were eligible. Guidelines for target definition and delineation, dose prescription, and dose-volume constraints for the targets and critical normal structures were detailed in the study protocol and a web-based atlas. Results Fifty-eight patients were accrued by 25 institutions; 43 were eligible for analysis. Forty-two patients (98%) had an acceptable IMRT plan; 1 had an unacceptable variation from the prescribed dose to the nodal planning target volume. The proportions of cases in which doses to critical normal structures exceeded protocol criteria were as follows: bladder, 67%; rectum, 76%; bowel, 17%; and femoral heads, 33%. Twelve patients (28%) developed grade ≥2 short-term bowel adverse events. Conclusions Pelvic IMRT for endometrial cancer is feasible across multiple institutions with use of a detailed protocol and centralized quality assurance (QA). For future trials, contouring of vaginal and nodal tissue will need continued monitoring with good QA and better definitions will be needed for organs at risk.

Published
2011

6. 4. Forensic Examinations in Two Cases of Alleged Dowry Deaths

Author

J R Gaur

Subjects
medicine.medical_specialty, business.industry, Health Policy, Poison control, Dowry, medicine.disease, Suicide prevention, Occupational safety and health, Forensic science, Issues, ethics and legal aspects, Family medicine, Accidental, Injury prevention, medicine, Medical emergency, business, Law, Cause of death
Abstract

Two cases of alleged dowry deaths are presented from Haryana State, India. In each case a young lady died after receiving burn injuries. Forensic examination unveiled the mysteries of both deaths and helped in apprehending and prosecuting the culprits. Case 1, allegedly a dowry death, proved to be an accidental burning and Case 2, stated to be a suicidal death, was proved to be homicidal.

Published
1993

8. Experience of Alk Mutation Testing in 3351 Indian Patients of Nsclc

Author

Suresh H. Advani, P.S. Dattatreya, B.N. Dhabhar, S. Chatterjee, P.V.A. Reddy, T. Raja, S. Patil, Keechilat Pavithran, R. Gaur, S. Dutt, S. Srinivasan, R.G. Nambiar, and D.K. Mishra

Subjects
Oncology, medicine.medical_specialty, business.industry, ALK Gene Rearrangement, Hematology, Gene rearrangement, medicine.disease, Exon, Internal medicine, Cancer research, Mutation testing, Medicine, Adenocarcinoma, Anaplastic lymphoma kinase, Biomarker (medicine), business, Lung cancer
Abstract

Aim: In the last decade, we have witnessed a revolution in the molecular genetics of NSCLC (Non Small Cell Lung Cancer). These advances have led to the development of a multitude of prognostic and predictive biomarkers. Somatic mutations in EGFR (Epidermal Growth Factor Receptor) gene & ALK (Anaplastic Lymphoma Kinase) translocation are two “actionable” biomarkers that have passed clinical validation and are incorporated into current treatment paradigms. This abstract contributes towards understanding the epidemiology of ALK mutation in NSCLC patients in India. Methods: This was an observational study within the cohort of NSCLC patients. Pfizer Ltd supported this study as a part of Diagnostic Assistance Program. A total of 3351 patients of lung adenocarcinoma were tested from Jan 2013 to Mar 2014. These samples were collected from various locations across the country. ALK mutation was studied using the FDA approved Vysis ALK Gene Breakapart Probe Kit and the EGFR mutation testing (exons 18-21) was done using PCR followed by bidirectional Sanger's Sequencing. Results: Of the 3351 samples tested, 2146 (64.04%) were male & 1205 (35.96%) were females. Patients ranged in age from 25-90yrs with a median age of 57.94yrs. Biomarker testing for EGFR and ALK was performed on FFPE specimen of patients with confirmed adenocarcinoma histology. ALK testing was performed on 3351 samples and EGFR analysis on 3079. Of samples received for EGFR, 2653 (86.16%) were successfully analyzed & reported, 177 (5.75%) showed unsatisfactory results, and test could not be performed in 249 cases (8.09%). 2810 (83.86%) samples received for ALK testing by FISH could be successfully reported, 287 (8.56%) showed unsatisfactory results and 254 samples (7.58%) could not be tested. Common reasons for unsatisfactory results were presence of high degree of necrosis, scanty tumor or suboptimal fixation. Of the successfully reported cases, 28.19% were positive for presence of EGFR mutations. Mutations were observed in exon 18 (2.27%), exon 19 (72.99%), exon 20 (3.48%) and exon 21 (21.26%). 71 (2.53%) of the 2810 successfully reported cases were found Positive for ALK Gene Rearrangement. None of the samples showed a concomitant mutation. Conclusions: This study on 3351 adenocarcinoma enriched NSCLC patients of Indian origin, shows an ALK positivity of 2.53% & EGFR mutation positivity of 28.19%. Disclosure: All authors declare that he study was funded by Pfizer Ltd as a part of its Diagnostic Assistance Program. Other than that there is no disclosure to declare.

Published
2014

10. A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvic for Post-operative Patients with Endometrial Carcinoma (RTOG 0418)

Author

David K. Gaffney, Luis Souhami, Kathryn Winter, Mohammad Salehpour, Lawrence Berk, Brigitte Miller, William Small, Anuja Jhingran, R. Gaur, and L. Portelance

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Phases of clinical research, Intensity-modulated radiation therapy, medicine.disease, Internal medicine, medicine, Carcinoma, Radiology, Nuclear Medicine and imaging, Radiology, Post operative, business
Published
2008

11. Efficacy and Safety of IMRT after Surgery in Patients with Endometrial Cancer: RTOG 0418 Phase II Study

Author

Brigitte Miller, Anuja Jhingran, R. Gaur, David K. Gaffney, Luis Souhami, Kathryn Winter, Lorraine Portelance, Mohammad Salehpour, and William Small

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Endometrial cancer, Phases of clinical research, medicine.disease, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, In patient, business
Published
2011

12. Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer

Author

Luis Souhami, David D'Souza, Ann H. Klopp, R. Gaur, Mohammad Salehpour, Jennifer Moughan, William Small, Lorraine Portelance, Anuja Jhingran, and B.E. Miller

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Endometrial cancer, Phases of clinical research, Hematologic toxicity, Intensity-modulated radiation therapy, medicine.disease, medicine.anatomical_structure, Internal medicine, Gynecologic cancer, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, Bone marrow, Post operative, business, Prospective cohort study
Abstract

Purpose Intensity modulated radiation therapy (IMRT), compared with conventional 4-field treatment, can reduce the volume of bone marrow irradiated. Pelvic bone marrow sparing has produced a clinically significant reduction in hematologic toxicity (HT). This analysis investigated HT in RTOG 0418, a prospective study to test the feasibility of delivering postoperative IMRT for cervical and endometrial cancer in a multi-institutional setting.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results